Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Xencor (XNCR)

Xencor 2024 net loss widened to $232.6 million as revenue fell to $110.5 million

Negative Impact 3 of 5 earnings Written later

Xencor reported fourth-quarter and full-year 2024 results. Full-year revenue fell to $110.5 million from $174.6 million, and the net loss attributable to Xencor widened to $232.6 million, or $(3.58) per share, from $133.1 million, or $(2.20) per share. For shareholders, the filing also gives a 2025 year-end cash guidance range of $535 million to $585 million.

Key points

  • Q4 2024 revenue was $52.8 million, up from $51.0 million, driven mainly by Amgen and Novartis milestone revenue
  • Q4 2024 net loss attributable to Xencor was $45.6 million, or $(0.62) per share, versus $26.1 million, or $(0.43), a year earlier
  • Cash, cash equivalents and marketable debt securities were $706.7 million at December 31, 2024, up from $697.0 million
  • Company expects to end 2025 with between $535 million and $585 million in cash and marketable debt securities

The filing

CompanyXencor (XNCR)
Form8-K, current report
Filed with the SECFeb 27, 2025, 8:02 AM ET
Accession number0001326732-25-000028

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.